Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Del Carpio, Luis P.
• dc.contributor.author Algarra, María Asunción
• dc.contributor.author Sabaté-Llobera, Aida
• dc.contributor.author Rodriguez-Vida, Alejo
• dc.contributor.author Rossi-Seoane, Susana
• dc.contributor.author Ruiz, Sandra
• dc.contributor.author Leiva, David
• dc.contributor.author Ramos, Emilio
• dc.contributor.author Lladò, Laura
• dc.contributor.author Lorenzo, Daniel
• dc.contributor.author Gutiérrez, Cristina
• dc.contributor.author Cortes-Romera, Montserrat
• dc.contributor.author Caminal, Josep Maria
• dc.contributor.author Piulats, Josep Maria
• dc.date.accessioned 2024-02-27T07:22:03Z
• dc.date.available 2024-02-27T07:22:03Z
• dc.date.issued 2023
• dc.description.abstract Background: Uveal melanoma metastasizes to the liver. We aimed to explore the metabolic activity of liver metastases (LM) as a biomarker for survival. Methods: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver-directed imaging and had undergone a PET/CT at diagnosis. Findings: 51 patients were identified between 2004 and 2019. Median age was 62 years, 41% male and 22% ECOG ≥1. LDH, ALP, and GGT were elevated in 49%, 37%, and 57% of patients. Median LM SUVmax was 8.5 (3-42.2). Same size lesions presented a wide range of metabolic activity. Median OS was 17.3 m (95% CI:10.6-23.9). Patients with SUVmax ≥8.5 had an OS of 9.4 m (95% CI:6.4-12.3), whereas patients with SUVmax <8.5 had an OS of 38.4 m (95% CI:21.4-55.5; p < 0.0001, HR = 2.9). We observed similar results when studying M1a disease separately. Multivariate analysis showed SUVmax as an independent prognostic factor for the whole population and those with M1a disease. Interpretation: Increased metabolic activity of LM seems to be an independent predictor of survival. MUM is a heterogeneous disease and metabolic activity probably reflects a different intrinsic behavior.
• dc.format.mimetype application/pdf
• dc.identifier.citation Del Carpio LP, Algarra MA, Sabaté-Llobera A, Rodriguez-Vida A, Rossi-Seoane S, Ruiz S, Leiva D, Ramos E, Lladò L, Lorenzo D, Gutierrez C, Cortes-Romera M, Caminal JM, Piulats JM. Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis. Cancer Med. 2023 Jul;12(13):14062-71. DOI: 10.1002/cam4.6058
• dc.identifier.doi http://dx.doi.org/10.1002/cam4.6058
• dc.identifier.issn 2045-7634
• dc.identifier.uri http://hdl.handle.net/10230/59267
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Cancer Med. 2023 Jul;12(13):14062-71
• dc.rights © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword PET/CT
• dc.subject.keyword Glucose metabolism
• dc.subject.keyword Liver metastasis
• dc.subject.keyword Prognostic
• dc.subject.keyword Uveal melanoma
• dc.title Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion